Exscientia (NASDAQ:EXAI) Given “Equal Weight” Rating at Morgan Stanley

Morgan Stanley reaffirmed their equal weight rating on shares of Exscientia (NASDAQ:EXAI) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Bank of America cut Exscientia from a buy rating to a neutral rating and cut their target price for the company from $11.00 to $9.00 in a research report on Friday, January 5th.

Exscientia Trading Up 0.2 %

Shares of EXAI stock opened at $4.25 on Monday. The stock has a 50-day moving average of $5.75 and a 200-day moving average of $5.86. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05. The stock has a market cap of $513.77 million, a price-to-earnings ratio of -2.87 and a beta of 0.78. Exscientia has a 1-year low of $4.14 and a 1-year high of $9.12.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. The business had revenue of $3.10 million during the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. On average, equities research analysts forecast that Exscientia will post -1.76 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXAI. GAMMA Investing LLC increased its position in Exscientia by 112.1% in the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after buying an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Exscientia by 359.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after acquiring an additional 4,104 shares during the last quarter. Values First Advisors Inc. raised its stake in Exscientia by 10.0% in the 4th quarter. Values First Advisors Inc. now owns 55,958 shares of the company’s stock valued at $359,000 after acquiring an additional 5,090 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Exscientia by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 27,275 shares of the company’s stock valued at $175,000 after purchasing an additional 6,916 shares during the last quarter. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in Exscientia during the fourth quarter worth about $64,000. 41.58% of the stock is currently owned by hedge funds and other institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.